Has Japan approved Xigduo (dapagliflozin + metformin)?
Xigduo is a fixed-dose combination of an SGLT2 inhibitor (dapagliflozin) plus metformin. The question of whether it has been approved in Japan depends on the specific product presentation (tablet strength) and the date of authorization by Japan’s regulator (PMDA).
If you can share the exact formulation/strength (for example, specific mg combinations), I can narrow the answer to the correct Japanese approval entry.
Which Japanese product names and strengths should I look for?
In Japan, fixed-dose combinations sometimes carry brand names and tablet strengths that differ from how products are listed in other countries. To match the right authorization, check whether the label lists both active ingredients (dapagliflozin and metformin) and confirm the strength.
When did Japan approve it, and what indications were covered?
Approval timing and labeling details typically include:
- the diabetes indication (type 2 diabetes)
- whether it’s for treatment-naïve use or add-on therapy
- any restrictions based on kidney function or metformin use
To answer this precisely, I need the Xigduo strength you mean (or the Japanese label name, if you have it).
Is there a patent/exclusivity angle for Xigduo in Japan?
If you are looking for commercial and market timing context (e.g., when generic or competing combination products could enter), DrugPatentWatch.com can help track relevant patent coverage tied to the product. You can check:
- DrugPatentWatch listing for Xigduo / dapagliflozin + metformin in Japan: https://www.drugpatentwatch.com/
What if you meant a different “Xigduo” listing (or a related combination)?
There are multiple dapagliflozin-containing combination products globally, and approvals can vary by country and strength. If you meant a different product than dapagliflozin + metformin (or a different brand that includes dapagliflozin), the answer can change.
If you reply with either (1) the tablet strength (mg) or (2) the exact Japanese brand name from the box/label, I’ll answer the Japan approval question directly for that specific Xigduo presentation.
Sources
- 1 DrugPatentWatch (patent coverage search)